Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNST NASDAQ:GTHX NASDAQ:SNDX NASDAQ:TRIL NASDAQ:ZGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNSTConstellation Pharmaceuticals$33.99$33.89$17.00▼$39.30$1.63B2.59940,325 shsN/AGTHXG1 Therapeutics$7.15$7.13$1.08▼$7.19$373.81M1.661.70 million shsN/ASNDXSyndax Pharmaceuticals$9.46-2.2%$9.88$8.58▼$25.07$832.08M0.71.87 million shs1.90 million shsTRILTrillium Therapeutics$18.44$18.12$5.80▼$20.96$1.94B2.081.87 million shs8 shsZGNXZogenix$26.68$26.52$11.03▼$26.90$1.50B0.893.76 million shs94 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNSTConstellation Pharmaceuticals0.00%0.00%0.00%0.00%0.00%GTHXG1 Therapeutics0.00%0.00%0.00%0.00%+103.13%SNDXSyndax Pharmaceuticals+4.54%-1.53%+0.31%-15.95%-59.18%TRILTrillium Therapeutics0.00%0.00%0.00%0.00%0.00%ZGNXZogenix0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AGTHXG1 TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASNDXSyndax Pharmaceuticals3.085 of 5 stars3.50.00.04.42.40.00.0TRILTrillium TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNSTConstellation Pharmaceuticals 0.00N/AN/AN/AGTHXG1 Therapeutics 2.00HoldN/AN/ASNDXSyndax Pharmaceuticals 2.90Moderate Buy$34.10260.47% UpsideTRILTrillium Therapeutics 0.00N/AN/AN/AZGNXZogenix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest CNST, ZGNX, TRIL, GTHX, and SNDX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/15/2025SNDXSyndax PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$37.00 ➝ $35.007/10/2025SNDXSyndax PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$18.005/6/2025SNDXSyndax PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$16.00 ➝ $17.005/6/2025SNDXSyndax PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNSTConstellation PharmaceuticalsN/AN/AN/AN/A$8.63 per shareN/AGTHXG1 Therapeutics$58.20M6.42N/AN/A$0.68 per share10.51SNDXSyndax Pharmaceuticals$23.68M34.38N/AN/A$3.38 per share2.80TRILTrillium Therapeutics$150K12,907.39N/AN/A$2.56 per share7.20ZGNXZogenix$81.69M18.36N/AN/A$6.64 per share4.02Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNSTConstellation Pharmaceuticals-$126.36M-$2.81N/AN/AN/AN/A-33.12%-29.92%N/AGTHXG1 Therapeutics-$47.97M-$0.62N/AN/AN/A-76.93%-136.98%-39.33%N/ASNDXSyndax Pharmaceuticals-$318.76M-$3.860.00N/AN/A-757.53%-101.60%-58.41%8/7/2025 (Estimated)TRILTrillium Therapeutics-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/AZGNXZogenix-$209.38M-$4.07N/AN/AN/A-278.38%-91.20%-43.60%N/ALatest CNST, ZGNX, TRIL, GTHX, and SNDX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025SNDXSyndax Pharmaceuticals-$0.99N/AN/AN/AN/AN/A5/5/2025Q1 2025SNDXSyndax Pharmaceuticals-$1.04-$0.98+$0.06-$0.98$15.88 million$20.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/AGTHXG1 TherapeuticsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ATRILTrillium TherapeuticsN/AN/AN/AN/AN/AZGNXZogenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNSTConstellation PharmaceuticalsN/A15.3915.39GTHXG1 Therapeutics1.342.482.12SNDXSyndax Pharmaceuticals1.535.805.75TRILTrillium TherapeuticsN/A19.8219.82ZGNXZogenix0.883.634.74Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNSTConstellation PharmaceuticalsN/AGTHXG1 Therapeutics24.21%SNDXSyndax PharmaceuticalsN/ATRILTrillium Therapeutics87.15%ZGNXZogenixN/AInsider OwnershipCompanyInsider OwnershipCNSTConstellation Pharmaceuticals43.70%GTHXG1 Therapeutics6.11%SNDXSyndax Pharmaceuticals4.10%TRILTrillium Therapeutics9.10%ZGNXZogenix4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNSTConstellation Pharmaceuticals15447.92 millionN/ANot OptionableGTHXG1 Therapeutics17052.28 million49.09 millionOptionableSNDXSyndax Pharmaceuticals11086.05 million82.52 millionOptionableTRILTrillium Therapeutics33105.00 million95.44 millionOptionableZGNXZogenix21856.23 million53.92 millionOptionableCNST, ZGNX, TRIL, GTHX, and SNDX HeadlinesRecent News About These CompaniesAfter epilepsy setback, Zogenix buys Modis and rare disease drug for $400mJanuary 2, 2025 | pharmaphorum.comPNeedle-Free Drug Injection Systems Business Analysis Report 2023-2030 Featuring AKRA Dermojet, Crossject, D`Antonio Consultants, PharmaJet, and ZogenixAugust 1, 2024 | globenewswire.comHwasung Industrial Co Ltd 002460March 23, 2024 | morningstar.comMOrally Inhaled DihydroergotamineFebruary 13, 2024 | medscape.comMMRI in HeadacheAugust 25, 2023 | medscape.comMKratom: What We KnowAugust 13, 2023 | medscape.comMAlcon (NYSE: ALC)July 6, 2023 | fool.comLongeveron Inc Ordinary Shares - Class AMay 20, 2023 | morningstar.comMDravet Syndrome Market Report 2032: Epidemiology Data, Pipeline ... - Digital JournalMay 10, 2023 | news.google.comNGlobal Needle Free Diabetes Management Market Size 2023 ... - The Northwestern ExaminerMay 8, 2023 | news.google.comNGlobal Needle-Free Drug Delivery Systems Market New ... - The Northwestern ExaminerMay 8, 2023 | news.google.comNNeedle Free Injection Systems Market Size Reach Valuation of USD 519.3 Million in 2030 - Emergen Research - openPRMay 4, 2023 | news.google.comNNeedle Free Diabetes Management Market Forecast 2023 – 2032 ... - Taiwan NewsApril 28, 2023 | news.google.comNThe Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine HeadacheApril 25, 2023 | medscape.comMLong-Acting Injectable Antipsychotics Market 2023-2033: Global ... - Taiwan NewsApril 24, 2023 | news.google.comNAnti-epileptic Drugs Market Expected to Expand at a Steady 2023 ... - Digital JournalApril 24, 2023 | news.google.comNDravet Syndrome Pipeline Assessment (2023 Updates) | In-depth ... - Digital JournalApril 19, 2023 | news.google.comNForm SC 14D9/A Provention Bio, Inc. Filed by: Provention Bio, Inc. - StreetInsider.comApril 19, 2023 | news.google.comNDEA lifts Dravet therapy Fintepla's controlled substance status |... - Dravet Syndrome NewsApril 18, 2023 | news.google.comNUCB Announces FINTEPLA® (fenfluramine) Oral Solution Is Now ... - Longview News-JournalApril 17, 2023 | news.google.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeDan Ives’ Bold $5 Trillion Forecast for Microsoft StockBy Chris Markoch | July 2, 2025View Dan Ives’ Bold $5 Trillion Forecast for Microsoft StockMarketBeat Week in Review – 07/07 - 07/11By MarketBeat Staff | July 12, 2025View MarketBeat Week in Review – 07/07 - 07/11CNST, ZGNX, TRIL, GTHX, and SNDX Company DescriptionsConstellation Pharmaceuticals NASDAQ:CNSTConstellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.G1 Therapeutics NASDAQ:GTHXG1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Syndax Pharmaceuticals NASDAQ:SNDX$9.46 -0.21 (-2.17%) Closing price 04:00 PM EasternExtended Trading$9.40 -0.06 (-0.64%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Trillium Therapeutics NASDAQ:TRILTrillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.Zogenix NASDAQ:ZGNXZogenix, Inc. is a pharmaceutical company. The firm engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include Fintepla and MT1621. The company was founded by Stephen James Farr, Cam L. Garner, Roger L. Hawley, Bret E. Megargel, Jonathan M. N. Rigby, Scott L. Glenn, and John J. Turanin on May 11, 2006 and is headquartered in Emeryville, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era How Goldman Sachs Earnings Help You Strategize Your Portfolio Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
